Kliniken & Institute … Institute Zentrum für… Parasitology Unit Research Current Groups Lanzer Lab

Malaria Research: Lanzer

The Lanzer lab from left to right: Nisha Veits (BSc student, alumna), Fiona Berger (PhD student), Marina Müller (technician), Marianne Papagrigorakes (PhD student), Atdhe Kernaja (technician), Romina Celada (PhD student), Britta Nyboer (Postdoc, alumna), Michael Lanzer (group leader). Not on the photo: Guillermo Gómez (PhD student), Violeta Pancakova (PhD student), Cecilia Sanchez (senior scientist).

Research interest

The pathogenicity of human malaria parasites

The pioneering work of Sir Ronald Ross, demonstrating that malaria is a vector-borne disease, celebrated its centennial anniversary in 1997. More than one-hundred years later, malaria still remains a major threat to mankind, responsible for an estimated 250 million clinical cases and almost 1 million deaths annually. The malaria situation is expected to get worse as once effective weapons against this infectious disease have lost their edge. Chemotherapeutics now frequently fail due to wide spread resistance mechanisms, and insecticides, once widely used to eradicate the malaria vectors, are now disqualified because of environmental considerations. New and affordable drugs, suitable for mass application in developing countries, are not on the horizon, neither is a widely effective malaria vaccine. In order to develop sustainable means to control malaria, a better understanding of the etiological agents that cause malaria, their biology, virulence and pathogenicity is imperative.

Our objectives are to provide a better understanding of the biology, virulence and pathogenicity of malaria parasites, in an effort to develop new regimens for the treatment of this important disease. In particular, we are investigating:

  • the molecular mechanisms of immune evasion and cytoadhesion and how these pathogenetic mechanisms affect the pathogenesis of the disease;
  • the genesis of chloroquine drug resistance;
  • mechanisms of ion homeostasis;
  • the application of ionic exchangers as novel targets for rational drug development programs.

Wai CH, Jin J, Cyrklaff M, Genoud C, Funaya C, Sattler J, Maceski A, Meier S, Heiland S, Lanzer M, Frischknecht F, Kuhle J, Bendszus M, Hoffmann A (2022) Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria. Sci Rep. Jun 24;12(1):10726. doi: 10.1038/s41598-022-14291-x. PMID: 35750882; PMCID: PMC9232608.

Jäger J, Patra P, Sanchez CP, Lanzer M, Schwarz US (2022) A particle-based computational model to analyse remodelling of the red blood cell cytoskeleton during malaria infections. PLoS Comput Biol. Apr 8;18(4):e1009509. doi: 10.1371/journal.pcbi.1009509. PMID: 35394995.

Jin J, Ba MA, Wai CH, Mohanty S, Sahu PK, Pattnaik R, Pirpamer L, Fischer M, Heiland S, Lanzer M, Frischknecht F, Mueller AK, Pfeil J, Majhi M, Cyrklaff M, Wassmer SC, Bendszus M, Hoffmann A (2022) Transcellular blood-brain barrier disruption in malaria-induced reversible brain edema. Life Sci Alliance. Mar 8;5(6):e202201402. doi: 10.26508/lsa.202201402. PMID: 35260473; PMCID: PMC8905774.

Sanchez CP, Patra P, Chang SS, Karathanasis C, Hanebutte L, Kilian N, Cyrklaff M, Heilemann M, Schwarz US, Kudryashev M, Lanzer M (2022) KAHRP dynamically relocalizes to remodeled actin junctions and associates with knob spirals in Plasmodium falciparum-infected erythrocytes. Mol Microbiol. Feb;117(2):274-292. doi: 10.1111/mmi.14811. Epub 2021 Sep 22. PMID: 34514656.

Dijkman PM, Marzluf T, Zhang Y, Chang SS, Helm D, Lanzer M, Bujard H, Kudryashev M (2021) Structure of the merozoite surface protein 1 from Plasmodium falciparum. Sci Adv. Jun 2;7(23):eabg0465.

Fröhlich B, Dasanna AK, Lansche C, Czajor J, Sanchez CP, Cyrklaff M, Yamamoto A, Craig A, Schwarz US, Lanzer M, Tanaka M (2021) Functionalized supported membranes for quantifying adhesion of P. falciparum-infected erythrocytes. Biophys J. Jul 8:S0006-3495(21)00552-X

Bukau B, Lanzer M, Melchers F, Wallon G (2020) Hermann Bujard (1934 - 2020) - pioneering researcher and visionary science politician. EMBO J.  Dec 1;39(23):e106981 

Frohlich B, Yang Y, Thoma J, Czajor J, Lansche C, Sanchez C, Lanzer M, Cloetens P, Tanaka M (2020) Nanofocused Scanning X-ray Fluorescence Microscopy Revealing an Effect of Heterozygous Hemoglobin S and C on Biochemical Activities in Plasmodium falciparum-Infected Erythrocytes. Anal Chem 92: 5765-5771

Blank A, Furle K, Jaschke A, Mikus G, Lehmann M, Husing J, Heiss K, Giese T, Carter D, Bohnlein E, Lanzer M, Haefeli WE, Bujard H (2020) Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial. NPJ Vaccines 5: 10

Jankowska-Dollken M, Sanchez CP, Cyrklaff M, Lanzer M (2019) Overexpression of the HECT ubiquitin ligase PfUT prolongs the intraerythrocytic cycle and reduces invasion efficiency of Plasmodium falciparum. Scientific reports 9: 18333

Frohlich B, Jager J, Lansche C, Sanchez CP, Cyrklaff M, Buchholz B, Soubeiga ST, Simpore J, Ito H, Schwarz US, Lanzer M, Tanaka M (2019) Hemoglobin S and C affect biomechanical membrane properties of P. falciparum-infected erythrocytes. Communications biology 2: 311

Sanchez CP, Moliner Cubel S, Nyboer B, Jankowska-Dollken M, Schaeffer-Reiss C, Ayoub D, Planelles G, Lanzer M (2019) Phosphomimetic substitution at Ser-33 of the chloroquine resistance transporter PfCRT reconstitutes drug responses in Plasmodium falciparum. J Biol Chem

Sanchez CP, Karathanasis C, Sanchez R, Cyrklaff M, Jager J, Buchholz B, Schwarz US, Heilemann M, Lanzer M (2019) Single-molecule imaging and quantification of the immune-variant adhesin VAR2CSA on knobs of Plasmodium falciparum-infected erythrocytes. Communications biology 2: 172

Lansche C, Dasanna AK, Quadt K, Fröhlich B, Missirlis D, Tétard M, Gamain B, Buchholz B, Sanchez CP, Tanaka M, Schwarz US, Lanzer M (2018) The sickle cell trait affects contact dynamics and endothelial cell activation in Plasmodium falciparum-infected erythrocytes. Communications Biology 1: 211 Full Text

Duffey M, Sanchez CP, Lanzer M (2018) Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum. Malar J 17: 121

Frank V, Chushkin Y, Frohlich B, Abuillan W, Rieger H, Becker AS, Yamamoto A, Rossetti FF, Kaufmann S, Lanzer M, Zontone F, Tanaka M (2017) Lensless Tomographic Imaging of Near Surface Structures of Frozen Hydrated Malaria-Infected Human Erythrocytes by Coherent X-Ray Diffraction Microscopy. Scientific reports 7: 14081

Djuika CF, Staudacher V, Sanchez CP, Lanzer M, Deponte M (2017) Knockout of the peroxiredoxin 5 homologue PFAOP does not affect the artemisinin susceptibility of Plasmodium falciparum. Scientific reports 7: 4410

Dasanna AK, Lansche C, Lanzer M, Schwarz US (2017) Rolling Adhesion of Schizont Stage Malaria-Infected Red Blood Cells in Shear Flow. Biophysical journal 112: 1908-1919

Bakouh N, Bellanca S, Nyboer B, Moliner Cubel S, Karim Z, Sanchez CP, Stein WD, Planelles G, Lanzer M (2017) Iron is a substrate of the Plasmodium falciparum chloroquine resistance transporter PfCRT in Xenopus oocytes. J Biol Chem 292: 16109-16121

Jida M, Sanchez CP, Urgin K, Ehrhardt K, Mounien S, Geyer A, Elhabiri M, Lanzer M, Davioud-Charvet E (2017) A Redox-Active Fluorescent pH Indicator for Detecting Plasmodium falciparum Strains with Reduced Responsiveness to Quinoline Antimalarial Drugs. ACS infectious diseases 3: 119-131                  

Waldecker M, Dasanna AK, Lansche C, Linke M, Srismith S, Cyrklaff M, Sanchez CP, Schwarz US, Lanzer M (2017) Differential time-dependent volumetric and surface area changes and delayed induction of new permeation pathways in P. falciparum-infected hemoglobinopathic erythrocytes. Cell Microbiol 19

Urgin K, Jida M, Ehrhardt K, Muller T, Lanzer M, Maes L, Elhabiri M, Davioud-Charvet E (2017) Pharmacomodulation of the Antimalarial Plasmodione: Synthesis of Biaryl- and N-Arylalkylamine Analogues, Antimalarial Activities and Physicochemical Properties. Molecules 22

Pegoraro S, Duffey M, Otto TD, Wang Y, Rosemann R, Baumgartner R, Fehler SK, Lucantoni L, Avery VM, Moreno-Sabater A, Mazier D, Vial HJ, Strobl S, Sanchez CP, Lanzer M (2017) SC83288 is a clinical development candidate for the treatment of severe malaria. Nature communications 8: 14193

News - Lanzer group

How to get in touch:

Prof. Dr. rer. nat. Michael Lanzer

Ärztlicher Direktor

06221 56-7845
06221 56-4643

Follow Prof. Lanzer: